Albuterol Sulfate Solution
Product Images NDC 0487-9904

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Albuterol Sulfate (NDC 0487-9904). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nephron Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F:\daisy Assignment\6月份\06.20\albuterol-sulfate-inhalation-solution-6-20-2008\figure-01.jpg (F269bd00 Figure 01)

Chemical structure of Albuterol Sulfate, showing the molecular arrangement including the phenol ring and side chains, representing two molecules complexed with sulfuric acid.*

FDA Label Image

F:\daisy Assignment\6月份\06.20\albuterol-sulfate-inhalation-solution-6-20-2008\figure-02.jpg (F269bd00 Figure 02)

Line graph titled '% Change from Pre-Dose FEV1, Intent-to-Treat Population Day 1'. It depicts percentage change on the y-axis and hours from pre-dose on the x-axis, comparing treatments with Albuterol 1.25 mg, Albuterol 0.63 mg, and placebo over a 6-hour period, showing trends of lung function improvement after dosing.*

FDA Label Image

F:\daisy Assignment\6月份\06.20\albuterol-sulfate-inhalation-solution-6-20-2008\figure-03.jpg (F269bd00 Figure 03)

A line graph depicting percent change from pre-dose FEV1 (forced expiratory volume in one second) over a 6-hour period on day 28 in an intent-to-treat population. The graph compares three treatments: albuterol 1.25 mg, albuterol 0.63 mg, and placebo, tracked by hours from pre-dose on the x-axis and percent change on the y-axis.*

FDA Label Image

F:\daisy Assignment\6月份\06.20\albuterol-sulfate-inhalation-solution-6-20-2008\figure-04.jpg (F269bd00 Figure 04)

An instructional illustration showing a person dispensing Albuterol Sulfate inhalation solution from a vial into a nebulizer cup, demonstrating proper use for respiratory inhalation.*

FDA Label Image

F:\daisy Assignment\6月份\06.20\albuterol-sulfate-inhalation-solution-6-20-2008\figure-05.jpg (F269bd00 Figure 05)

An instructional line drawing showing the assembly or connection of a respiratory inhalation device component, likely related to administration of Albuterol Sulfate solution. The image depicts close-up views of parts aligning for attachment.*

FDA Label Image

F:\daisy Assignment\6月份\06.20\albuterol-sulfate-inhalation-solution-6-20-2008\figure-06.jpg (F269bd00 Figure 06)

Illustration showing a person using a respiratory inhalation solution device, demonstrating proper technique by placing the mouthpiece in their mouth and holding the inhaler with their hand.*

FDA Label Image

F:\daisy Assignment\6月份\06.20\albuterol-sulfate-inhalation-solution-6-20-2008\figure-07.jpg (F269bd00 Figure 07)

An illustration showing a person using a respiratory inhalation device, likely demonstrating the administration of an inhalation solution. The person is inhaling through a mouthpiece attached to a nebulizer or similar device.*

FDA Label Image

F269bd00-figure-08 (F269bd00 Figure 08)

Albuterol Sulfate Inhalation Solution 1.25 mg/3 mL by Nephron Pharmaceuticals Corporation. The label shows sterile unit-dose vials containing 3 mL solution for oral inhalation. Packaging includes 30 foil pouches. The label indicates potency as albuterol equivalent and states the product is made in the USA.*

FDA Label Image

F269bd00-figure-09 (F269bd00 Figure 09)

Albuterol Sulfate Inhalation Solution 0.63 mg/3 mL vial label from Nephron Pharmaceuticals Corporation. The label indicates the product is sterile, prediluted with normal saline, for oral inhalation only, and comes in a package of 30 sterile unit-dose vials in foil pouches. It is marked as Rx only and made in the USA.*

FDA Label Image

F269bd00-figure-10 (F269bd00 Figure 10)

This image shows patient information and instructions for use of Albuterol Sulfate inhalation solution, including storage conditions, dosage form details, and step-by-step guidance on administering the solution using a nebulizer with figures illustrating vial removal, nebulizer connection, and inhalation positioning. A barcode and recycling symbol are also visible.*

FDA Label Image

F269bd00-figure-11 (F269bd00 Figure 11)

Label for Albuterol Sulfate Inhalation Solution 0.042%, 1.25 mg per 3 mL solution. The label states the product is for oral inhalation only and lists active and inactive ingredients, storage conditions, and usage instructions. It includes dosing precautions and is manufactured by Nephron Pharmaceuticals Corporation. The vial is a sterile, single-use 3 mL unit-dose.*

FDA Label Image

F269bd00-figure-12 (F269bd00 Figure 12)

Albuterol Sulfate Inhalation Solution 0.021% (0.63 mg/3 mL) single-dose vial label by Nephron Pharmaceuticals Corporation. The label includes dosage information for oral inhalation, active ingredient amount, inactive ingredients, storage instructions, and usage directions. It also provides patient instructions on vial and nebulizer use, a barcode, lot number, and manufacturer contact details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.